4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester CAS:571188-82-4

4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester, often referred to in research contexts as its chemical shorthand, represents a compound under investigation for various therapeutic purposes. This compound is structurally characterized by its complex arrangement of heterocyclic rings and functional groups, designed to interact with specific biological targets implicated in disease mechanisms. In pharmaceutical research, this compound's use centers around its potential as a therapeutic agent. The structural features, including the bromo and cyclopentyl groups, along with the pyrimidine and piperazine moieties, suggest a targeted approach towards modulating biochemical pathways associated with certain diseases. The pyrido[2,3-d]pyrimidine core, fused with a cyclopentyl ring and a bromine atom, enhances its pharmacological profile by potentially influencing receptor binding or enzymatic activity crucial to disease progression. Researchers are particularly interested in exploring its efficacy in preclinical models for conditions where similar chemical scaffolds have shown promise. This includes but is not limited to, neurodegenerative disorders, cancer, and infectious diseases. The compound's 1,1-dimethylethyl ester modification contributes to its stability and bioavailability, crucial for effective delivery and sustained activity within biological systems. Moreover, studies are ongoing to elucidate its pharmacokinetic and pharmacodynamic properties, aiming to optimize dosage regimens and minimize adverse effects. Its development pathway includes rigorous testing for safety, efficacy, and compatibility with existing therapeutic standards. Collaborative efforts between medicinal chemists, pharmacologists, and clinical researchers are pivotal in advancing its potential towards clinical trials and ultimately, regulatory approval. In conclusion, 4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester represents a promising candidate in the realm of drug discovery and development, poised to address unmet medical needs through innovative pharmacotherapy.